The present invention relates to silicon dioxide free orally disintegrating tablet formulations of zolmitriptan or a pharmaceutically acceptable salt thereof comprising magnesium carbonate heavy and sodium stearyl fumarate with one or more pharmaceutically acceptable excipient. Furthermore, the invention relates to the process for preparing such a formulation and its use in the treatment of migraine.